Evidence map›Paper›PMID 37311004›Full record

ArticlePLoS pathogens2023

Multidimensional analysis of immune cells from COVID-19 patients identified cell subsets associated with the severity at hospital admission.

Sergio Gil-Manso, Diego Herrero-Quevedo, Diego Carbonell, Marta Martínez-Bonet, Esther Bernaldo-de-Quirós, Rebeca Kennedy-Batalla, Jorge Gallego-Valle, Rocío López-Esteban, Elena Blázquez-López, Iria Miguens-Blanco and 3 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Viruses · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sergio Gil-MansoAdvanced ImmunoRegulation Group, Gregorio Marañón Health Research Institute (IiSGM), General University Hospital Gregorio Marañón, Madrid, Spain.
Diego Herrero-QuevedoSignal Processing and Communications Department, University Carlos III de Madrid, Leganés, Madrid, Spain.ORCID 0000-0001-9980-871X
Diego CarbonellDepartment of Hematology, General University Hospital Gregorio Marañón (HGUGM), Madrid, Spain.
Marta Martínez-BonetLaboratory of Immune-Regulation, Gregorio Marañón Health Research Institute (IiSGM), General University Hospital Gregorio Marañón, Madrid, Spain.
Esther Bernaldo-de-QuirósLaboratory of Immune-Regulation, Gregorio Marañón Health Research Institute (IiSGM), General University Hospital Gregorio Marañón, Madrid, Spain.
Rebeca Kennedy-BatallaLaboratory of Immune-Regulation, Gregorio Marañón Health Research Institute (IiSGM), General University Hospital Gregorio Marañón, Madrid, Spain.
Jorge Gallego-ValleAdvanced ImmunoRegulation Group, Gregorio Marañón Health Research Institute (IiSGM), General University Hospital Gregorio Marañón, Madrid, Spain.
Rocío López-EstebanLaboratory of Immune-Regulation, Gregorio Marañón Health Research Institute (IiSGM), General University Hospital Gregorio Marañón, Madrid, Spain.
Elena Blázquez-LópezGastroenterology-Digestive Service, General University Hospital Gregorio Marañón, Network of Hepatic and Digestive Diseases (CIBEREHD), Carlos III Health Institute (ISCIII), Madrid, Spain.
Iria Miguens-BlancoEmergency Department, General University Hospital Gregorio Marañón, Madrid, Spain.
Rafael Correa-RochaLaboratory of Immune-Regulation, Gregorio Marañón Health Research Institute (IiSGM), General University Hospital Gregorio Marañón, Madrid, Spain.
Vanessa Gomez-VerdejoSignal Processing and Communications Department, University Carlos III de Madrid, Leganés, Madrid, Spain.
Marjorie PionAdvanced ImmunoRegulation Group, Gregorio Marañón Health Research Institute (IiSGM), General University Hospital Gregorio Marañón, Madrid, Spain.ORCID 0000-0003-1828-4745

Funding

NIMHD NIH HHS L60 MD003727
6 · The paper itself

Abstract

backgroundSARS-CoV-2 emerged as a new coronavirus causing COVID-19, and it has been responsible for more than 760 million cases and 6.8 million deaths worldwide until March 2023. Although infected individuals could be asymptomatic, other patients presented heterogeneity and a wide range of symptoms. Therefore, identifying those infected individuals and being able to classify them according to their expected severity could help target health efforts more effectively. METHODOLOGY/PRINCIPAL

findingsTherefore, we wanted to develop a machine learning model to predict those who will develop severe disease at the moment of hospital admission. We recruited 75 individuals and analysed innate and adaptive immune system subsets by flow cytometry. Also, we collected clinical and biochemical information. The objective of the study was to leverage machine learning techniques to identify clinical features associated with disease severity progression. Additionally, the study sought to elucidate the specific cellular subsets involved in the disease following the onset of symptoms. Among the several machine learning models tested, we found that the Elastic Net model was the better to predict the severity score according to a modified WHO classification. This model was able to predict the severity score of 72 out of 75 individuals. Besides, all the machine learning models revealed that CD38+ Treg and CD16+ CD56neg HLA-DR+ NK cells were highly correlated with the severity. CONCLUSIONS/SIGNIFICANCE: The Elastic Net model could stratify the uninfected individuals and the COVID-19 patients from asymptomatic to severe COVID-19 patients. On the other hand, these cellular subsets presented here could help to understand better the induction and progression of the symptoms in COVID-19 individuals.

Indexed as

COVID-19Flow CytometryHospitalizationHospitalsHumansSARS-CoV-2

Identifiers

PMID37311004
PMCPMC10263360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.